Management of patients with gastroesophageal reflux disease. Clinical practice guideline. Update 2008;Manejo del paciente con erge. Guía de práctica clínica. Actualización 2008

Gastroenterologia y Hepatologia

Volumn 32, Issue 6, 2009, Pages 431-464

  Marzo, Mercè ^a   Carrillo, Ricard ^b   Mascort, Juan José ^c   Alonso, Pablo ^c   Mearin, Fermín ^d   Ponce, Julio ^d   Ferrándiz, Juan ^a   Fernández, Miren ^c   Martínez, Gerardo ^a   Sáez, Manuel ^a   Bonfill, Xavier ^c   Piqué, Josep Maria ^d  

^a Sociedad Española de Medicina de Familia   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Centro Cochrane Iberoamericano   (Spain)

^d AEG   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ALGORITHM; ARTICLE; BARRETT ESOPHAGUS; CLASSIFICATION; COMORBIDITY; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; INCIDENCE; MALE; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PREVALENCE; RISK FACTOR; STOMACH FUNDOPLICATION;

ADENOCARCINOMA; ALGORITHMS; ANTACIDS; BARRETT ESOPHAGUS; COMBINED MODALITY THERAPY; COMORBIDITY; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PREVALENCE; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 70350457804     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2009.04.004     Document Type: Article

References (137)

1. Dent J, El-Serag HB, WallanderMA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710-7.
2. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086-100.
3. Ponce J, Vegazo O, Beltran B, Jimenez J, Zapardiel J, Calle D, Iberge Study Group, et al. Prevalence of gastro-oesophageal reflux disease in Spain and associated factors. Aliment Pharmacol Ther. 2006;23:175-84.
4. Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract. 2005;18:393-400.
5. Mason J, Hungin AP. Review article: gastro-oesophageal reflux disease-the health economic implications. Aliment Pharmacol Ther. 2005;22(Suppl 1):20 31.
6. Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther. 2006;24:259-72.
7. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions [Editorial]. ACP J Club. 1995;123:A12.
8. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, GRADE Working Group, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
9. Fox M, Forgacs I. Gastro-oesophageal reflux disease. BMJ. 2006;332:88-93.
10. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidencebased consensus. Am J Gastroenterol. 2006;101:1900-20 quiz 1943.
11. Dent J, Armstrong D, Delaney B, Moayyedi P, Talley J, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut. 2004;53:1-24.
12. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, et al. Canadian Consensos Conference on the management of gastroesophageal reflux disease in adults-update 2004. Can J Gastroenterol. 2005;19:15-35.
13. Junghard O, Carlsson R, Lind T. Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials. Scand J Gastroenterol. 2003;38:1197-9.
14. Galmiche JP, Clouse RE, Balint A, Cook IJ, Kahrilas PJ, Paterson WG, et al. Functional esophageal disorders. Gastroenterology. 2006;130:1459-65.
15. DeVault KR, Castell DO. American College of Gastroenterology updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100: 190-200.
16. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990;335:205-8.
17. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology. 2006;131:390-401.
18. Nilsson S, Scheike M, Engblom D, Karlsson LG, Molstad S, Akerlind I, et al. Chest pain and ischaemic heart disease in primary care. Br J Gen Pract. 2003;53:378-82.
19. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease The Practice Parameters Committee of American College of Gastroenterology. Am J Gastroenterol. 1999;94:1434-42.
20. Fransen GA, Janssen MJ, Muris JW, Laheij RJ, Jansen JB. Metaanalysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. Aliment Pharmacol Ther. 2004;20: 1045-52.
21. Kapoor N, Bassi A, Sturgess R, Bodger K. Predictive value of alarm features in a rapid access upper gastrointestinal cancer service. Gut. 2005;54:40-5.
22. Jones R, Galmiche JP. Review: what do we mean by GERD?-definition and diagnosis. Aliment Pharmacol Ther. 2005;22(Suppl 1):2-10.
23. Rey E, Elola-Olaso CM, Rodríguez-Artalejo F, Locke 3rd GR, Díaz-Rubio M. Eur J Gastroenterol Hepatol. 2006;18:969-75.
24. Heading RC. Prevalence of gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl. 1999;231:3-8.
25. Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, Locke 3rd GR, Rodriguez-Artalejo F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther. 2004;19:95-105.
26. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17-26.
27. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40:275-85.
28. Moayyedi P, Axon ATR. Gastro-oesophageal reflux disease: the extent of the problem. Aliment Pharmacol Ther. 2005;22(Suppl 1):11-9.
29. Ruigomez A, Garcia Rodriguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastroesophageal reflux disease diagnosed in UK general practice. Aliment Pharmacol Ther. 2004;20:751-60.
30. Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001;18:1367-72.
31. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut. 2004;53:1730-5.
32. Kang JY. Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:705-17.
33. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005;22:749-57.
34. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199-211.
35. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101:2619-28.
36. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo Jr CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354:2340-8.
37. Ortiz V, Ponce M, Fernandez A, Martinez B, Ponce JL, Garrigues V, et al. Value of heartburn for diagnosing gastroesophageal reflux disease in severely obese patients. Obesity (Silver Spring). 2006;14:696-700.
38. Rey E, Moreno-Elola-Olaso C, Artalejo FR, Locke 3rd GR, Diaz-Rubio M. Association between weight gain and symptoms of gastroesophageal reflux in the general population. Am J Gastroenterol. 2006;101:229-33.
39. Nilsson M, Lagergren J. The relation between body mass and gastro-oesophageal reflux. Best Pract Res Clin Gastroenterol. 2004;18:1117-23.
40. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166: 965-71.
41. Pandolfino JE, Bianchi LK, Lee TJ, Hirano I, Kahrilas PJ. Esophagogastric junction morphology predicts susceptibility to exercise-induced reflux. Am J Gastroenterol. 2004;99:1430-6.
42. Ontario Guidelines for Peptic Ulcer Disease and Gastroesopha-geal Reflux. Primera edición, año 2000. http://www.thecem.net/Downloads/gerd.pdf. Revisado en diciembre 2006.
43. Bigard MA, Pelletier AL. Esophageal complications of non steroidal antiinflammatory drugs. Gastroenterol Clin Biol. 2004;3:C58-61.
44. Gordon C, Kang JY, Neild PJ, Maxwell JD. The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:719-32.
45. Gisbert JP, Piqué J. Indications and consequences of Helico-bacter pylori eradication on gastroesophageal reflux disease. Med Clin (Barc). 2005;124:697-709.
46. Delaney B, McColl K. Review article: Helicobacter pylori and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22(Suppl 1):32-40.
47. Delaney B, Moayyedi P, Forman D. Helicobacter pylori infection. Clin Evid. 2005;13:518-34.
48. Cameron AJ, Lagergren J, Henriksson C, Nyren O, Lock III GR, Pedersen NL. Gastroesophageal refluxx disease in monozygotic and dizygotic twins. Gastroenterology. 2002;122:55-9.
49. Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ. Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut. 2003;52:1085-9.
50. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett' columnar-lined oesophagus. A Report of the Working Party of the British Society of Gastroenterology, Noviembre de 2005. Disponible en: http://www.bsg.org.uk/.
51. Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess. 2006;10:1-158.
52. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut. 2005;54:1062-6.
53. Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162:1050-61.
54. Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol. 2005;162:454-60.
55. Mehta S, Johnson IT, Rhodes M. Systematic review: the chemoprevention of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2005;22:759-68.
56. Mashimo H, Wagh MS, Goyal RK. Surveillance and screening for Barrett esophagus and adenocarcinoma. J Clin Gastroenterol. 2005;39(4 Suppl 2):S33-41.
57. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?. Gut. 2005;54(Suppl 1):1-5.
58. Hungin AP, Raghunath AS, Wiklund I. Beyond heartburn: a systematic review of the extra-oesophageal spectrum of reflux-induced disease. Fam Pract. 2005;22:591-603.
59. Wang WH, Huang JQ, Zheng GF, Wong WM, Lam SK, Karlberg J, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch Intern Med. 2005;165:1222-8.
60. Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol. 2005;100:1226-32.
61. Irwing RS. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):80S-94S.
62. Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-speci- fic cough in children and adults (Cochrane Review). The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004823. DOI:10.1002/14651858.CD004823.
63. Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. 2006;332:11-7.
64. Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294:1534-40.
65. Qadeer MA, Phillips CO, Lopez AR, Steward DL, Noordzij JP, Wo JM, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101:2646-54.
66. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:385-92.
67. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003;2:CD001496.
68. Hopkins C, Yousaf U, Pedersen M. Acid reflux treatment for hoarseness. The Cochrane Database of Systematic Reviews 2007 Issue 1. Chichester: John Wiley & Sons, Ltd.; 2007.
69. Talley NJ. What the physician needs to know for correct management of gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol The. 2004;20(Suppl. 2):23-30.
70. Moayyedi P, Duffy J, Delaney B. New approaches to enhance the accuracy of the diagnosis of reflux disease. Gut. 2004;53(Suppl 4):55-7.
71. Shaw M. Diagnostic utility of reflux disease symptoms. Gut. 2004;53(Suppl 4):25-7.
72. Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ. 2000;162(12 Suppl):S3-S23.
73. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ. 1989;298:30-2.
74. Talley NJ, Stanghellini V, Heading RC, Kock KL, Malagelada JR, Tytgat GNJ. Functional gastroduodenal disorders. Gut. 1999;45(suppl 2):37-42.
75. Tack J, Talley N, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gatroenterology. 2006;130:1466-79.
76. Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, et al. The usefulness of a structured questionnaire in the assesment of symptomatic gastroesopha-geal reflux disease. Scand J Gastroenterol. 1998;33:1023-9.
77. Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc. 1994;69:539-47.
78. Fraser A, Delaney B, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol. 2005;100:442-52.
79. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140:518-27.
80. Vakil N. Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease?. Aliment Pharmacol Ther. 2005;22(Suppl. 1): 64-9.
81. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27-34.
82. Zaninotto G, Molena D, Ancona E. A prospective multicenter study on laparoscopic treatment of gastroesophageal reflux disease in Italy: type of surgery, conversions, complications, and early results. Study Group for the Laparoscopic Treatment of Gastroesophageal Reflux Disease of the Italian Society of Endoscopic Surgery (SICE). Surg Endosc. 2000;14:282-8.
83. Fullard M, Kang JY, Neild P, Poullis A, Maxwell JD. Systematic review: does gastro-oesophageal reflux disease progress?. Aliment Pharmacol Ther. 2006;24:33-45.
84. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management-The Genval Workshop Report. Gut. 1999;44(Supl. 2):S1-S16.
85. Lundell L, Dent J, Bennett JR, Blum AL, Amstrong D, Calmiche JP. Endoscopic assessment of oesophagitis-clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172-80.
86. Savary M, Miller G. The esophagus. Handbook and atlas of endoscopy. Solothurn, Switzerland: Grassmann; 1977. p. 135.
87. National Guidelines Research and Development Unit. Dyspepsia: managing adults in primary care. London: National Guidelines Research and Development Unit; 2004.
88. The Scottish Intercollegiate Guidelines Network (SIGN). Clinical launch of the SIGN Dyspepsia guideline. March 18, 2003.
89. Grupo de trabajo de la guía de práctica clínica sobre dispepsia. Manejo del paciente con dispepsia. Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y centro Cochrane Iberoamericano; 2003. Programa de Elaboración de Guía s d e P r áctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 3.
90. van Herwaarden MA, Smout AJ. Diagnosis of reflux disease. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:759-74.
91. Bodger K, Trudgill N. Guidelines for oesophageal manometry and pH monitoring. British Society of Gastroenterology. Guidelines in Gastroenterology. November 2006.
92. Hirano I, Richter JE, Practice Parameters Committee of the American College of Gastroenterology. ACG Practice Guidelines: Esophageal Reflux Testing. Am J Gastroenterol. 2007; 102:668-85.
93. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983;28:559-63.
94. Farup PG, Weberg R, Berstad A, Wetterhus S, Dahlberg O, Dybdahl J, et al. Low-dose antacids versus 400mg cimetidine twice daily for reflux oesophagitis. Scand J Gastroenterol. 1990;25:315-20.
95. Chatfield S. Comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin. 1999;15:152-9.
96. Castell DO, Dalton CB, Becker D, Sinclair J, Castell JA. Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal-strength antacid. Dig Dis Sci. 1992;37:589-93.
97. Stanciu C, Bennett JR. Alginate-antacid in the reduction of gastro-oesophageal reflux. Lancet. 1974;1:109-11.
98. Lai IR, Wu MS, Lin JT. Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease. World J Gastroenterol. 2006;12:747-54.
99. Monés J, Carrio I, Sainz S, Berna L, Clave P, Liszkay M, et al. Gastric emptying of two radiolabered antacids with simultaneous monitoring of gastric pH. Eur J Nucl Med. 1995;22: 1123-8.
100. Earnest D, Robinson M, Rodriguez-Stanley S, Ciociola AA, Jaffe P, Silver MT, et al. Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther. 2000;14:911-8.
101. Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastrooesophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25:143-53.
102. Moayyedi P, Delaney B, Forman D. Gastro-oesophageal reflux disease. In: Clinical Evidence. 13th ed. London: BMJ Publishing Group Ltd.; 2005.
103. Lohitnavy M, Lohitnavy O, Thangkeattiyanon, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30:201-6.
104. Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and effects on protease inhibitors. Ann Pharmacother. 2006;40: 1974-83.
105. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006;3:CD002095.
106. Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol. 1999;94:92-7.
107. Pirvulescu I, Gheorghe C, Becheanu G, Gheorghe L, Iacob R, Simionov I, et al. The efficiency of the treatment with famotidine in non-erosive gastroesofageal reflux disease. Archives de L'Union Medicale Balkanique. 2003;38:149-53.
108. Khan M, Santana J, Donellan C, Preston C, Moayyedi P. Pharmacological therapies in the short term treatment of oesophagitis. Cochrane Database Syst Rev (in press).
109. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;2:CD003245.
110. Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther. 2005;21:1299-312.
111. Talley NJ, Armstrong D, Junghard O, Wiklund I. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2006;24:371-6.
112. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther. 2001;15:227-31.
113. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastro-oesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized controlled trials. Clin Ther. 2001;23: 998-1017.
114. Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, et al. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20mg in acute treatment of reflux oesopha-gitis, followed by a maintenance open-label, low dose therapy with rabeprazole. Dig Liver Dis. 2005;37:741-50.
115. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001;15:1729-36.
116. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short term use. Alimen Pharmacol Ther. 2003;17:1237-45.
117. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther. 2006;24:743.
118. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452-8.
119. Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, Vavasseur F, Taccoen A, Fiorentini P, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther. 2005;21:575-82.
120. Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005;100: 1949-56.
121. Metz DC, Inadomi JM, Howden CW, Veldhuyzen van Zanten SJ, Bytzer P. On-Demand Therapy for Gastroesophageal Reflux Disease. Am J Gastroenterol. 2006;101:1-12.
122. Ontario Programe for optimal therapeutic. Ontario Guideline for peptic ulcer disease and gastroesophageal reflux. June, 2000. Disponible en: http://www.thecem.net/Downloads/gerd.pdf (consultado en marzo 2007).
123. Yang YX, Lewis J, Epstein S, Metz DC. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture. JAMA. 2006;296:2947-53.
124. Hansen AN, Wahlqvist P, Jorgensen E, Lund H, Moum B. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms -a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract. 2005;59:655-64.
125. Hansen AN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B. Long-term management of patients with symptoms of gastro-oesophageal reflux disease - a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract. 2006;60:15-22.
126. Shimizu Y, Dobashi K, Kobayashi S, Ohki I, Tokushima M, Kusano M, et al. A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease [Abstract]. Tohoku J Exp Med. 2006; 209:181-9.
127. Littner MR, Leung FW, Ballard 2nd ED, Huang B, Samra NK, Lansoprazole Asthma Study Group. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128:1128-35.
128. Wong CH, Chua CJ, Liam CK, Goh KL. Gastro-oesophageal reflux disease in 'difficultto-control' asthma: prevalence and response to treatment with acid suppressive therapy. Aliment Pharmacol Ther. 2006;23:1321-7.
129. Novitsky YW, Paton BL, Kercher KW, Heniford BT. Current aspects of surgical management of GERD. Surg Technol Int. 2006;15:53-62.
130. Allgood PC, Bachmann M. Medical or surgical treatment for chronic gastro-oesophageal reflux? A systematic review of Publisher evidence offectiveness. Eur J Surg. 2000;166: 713-21.
131. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Lamm M, et al. Long-term management of gastrooesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. Eur J Gastroenterol Hepatol. 2000;12:879-87.
132. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Liedman B, Hatlebakk JG, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. 2001;192:172-9.
133. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331-8.
134. Madan A, Minocha A. Despite high satisfaction, majority of gastro-oesophageal reflux disease patients continue to use proton pump inhibitors after antireflux surgery. Aliment Pharmacol Ther. 2006;23:601-5.
135. Jackson PG, Gleiber MA, Askari R, Evans SR. Predictors of outcome in 100 consecutive laparoscopic antireflux procedures. Am J Surg. 2001;181:231-5.
136. Catarci M, Gentileschi P, Papi C, Carrara A, Marrese R, Gaspari AL, et al. Evidence-based appraisal of antire. ux fundoplica-tion. Ann Surg. 2004;239:325-37.
137. Falk GW, Fennerty MB, Rothstein RI. AGA Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology. 2006;131: 1313-4.